¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"particle count"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • elementary particle
    ¼Ò¸³ÀÚ
  • ferromagnetic particle
    °­ÀÚ¼ºÀÔÀÚ
  • heredity particle
    À¯ÀüÀÔÀÚ
  • particle
    ÀÔÀÚ
  • particle accelerator
    ÀÔÀÚ°¡¼Ó±â
  • particle attraction
    ÀÔÀÚÀηÂ
  • particle concentration fluorescence
    ÀÔÀÚ³óÃàÇü±¤
  • particle immunoassay
    ÀÔÀڸ鿪ºÐ¼®(¹ý)
  • particle radiation
    ÀÔÀÚ¹æ»ç¼±
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • suspended particle
    ºÎÀ¯ÀÔÀÚ, ÇöŹÀÔÀÚ, ¶áÀÔÀÚ
  • viral particle
    ¹ÙÀÌ·¯½ºÀÔÀÚ, ¹ÙÀ̸®¿Â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • particle accelerator
    ÀÔÀÚ°¡¼Ó±â
  • particle attraction
    ÀÔÀÚÀηÂ
  • beta particle
    º£Å¸ÀÔÀÚ
  • charged particle
    ÇÏÀüÀÔÀÚ, ´ëÀüÀÔÀÚ
  • charged particle equilibrium
    ÇÏÀüÀÔÀÚÆòÇü, Àü±âÀÔÀÚÆòÇü
  • charged particle radiation
    ÇÏÀüÀÔÀÚ¹æ»ç¼±
  • coarse particle
    Á¶¸³ÀÚ, °ÅÄ£ÀÔÀÚ
  • defective interfering particle
    °á¼Õ°£¼·ÀÔÀÚ
  • diamagnetic particle
    ¹ÝÀÚ¼ºÀÔÀÚ
  • elementary particle
    »ý¼Ò¸³ÀÚ, ¼Ò¸³ÀÚ
  • ferromagnetic particle
    öÀÚ¼ºÀÔÀÚ
  • particle concentration fluorescence
    ÀÔÀÚ³óÃàÇü±¤
  • heredity particle
    À¯ÀüÀÔÀÚ
  • particle immunoassay
    ÀÔÀڸ鿪ºÐ¼®(¹ý)
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • PETINIA => particle-enhanced turbidimetric inhibition immunoassay
    ÀÔÀÚÁõ´ëºñʾïÁ¦¸é¿ªÃøÁ¤(¹ý)
  • alpha particle
    ¾ËÆÄÀÔÀÚ
  • heavy charged particle
    ÁßÇÏÀüÀÔÀÚ
  • heavy particle
    ÁßÀÔÀÚ(ñìí£í­).
  • heavy particle
    ÁßÀÔÀÚ
  • heredity particle
    À¯ÀüÀÔÀÚ(ë¶îîí£í­).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • differential leukocyte count
    °¨º°Ç÷±¸°è»ê<<¹éÇ÷±¸ÀÇ ¹éºÐÀ²>>
  • direct platelet count
    Á÷Á¢Ç÷¼ÒÆÇ°è»ê(¹ý)(?Ì´ËÛ̬˭Ë×ËÑ).
  • dust count
    ¸ÕÁö°è»ê¹ý(ÊÙË­Ë×ËÑ).
  • lcukocyte count
    ¹éÇ÷±¸°è»ê
  • leukocyte count
    ¹éÇ÷±¸°è»ê
  • natural count
    ÀÚ¿¬°è¼ö(~Ë­Ëà).
  • nominal count
    Ç¥½Ãº¯¼ö.
  • plating colony count technique
    ÆòÆÇ¹è¾ç Áý¶ô°è¼ö¹ý
  • radioactivity count
    ¹æ»ç´ÉÃøÁ¤
  • reticulocyte count
    ¸Á(»ó)ÀûÇ÷±¸»êÁ¤(ØÑßÒîåúìϹߩïÒ).
  • reticulocyte count
    ¸Á(»ó)ÀûÇ÷±¸»êÁ¤(ØÑßÒîåúìϹߩïÒ)
  • telogen count
    ÈÞÁö±â ¸ð¹ß°è¼ö
  • total bacterial count
    Ãѱռö
  • total count of bacteria
    Ãѱռö°èÃø(õÅж⦠ͪö°).
  • viable count of bacteria
    »ý±Õ¼ö°èÃø(ßæÐ¶â¦Íªö´).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • kappa particle
    Ä«ÆÄ ÀÔÀÚ(Ø£í­)
  • killer particle
    »ìÀÔÀÚ(߯أí­)
  • messenger ribonucleoprotein particle
    Àü·É(îîÖµ) ¸®º¸ÇÙ»ê(ß«)´Ü¹éÁú ÀÔÀÚ(Ó±ÛÜòõØ£í­)
  • particle diffusion
    ÀÔÀÚÈ®»ê(Ø£í­üªß¤)
  • particle electrophoresis
    ÀÔÀÚ Àü±â¿µµ¿(Ø£í­ï³Ñ¨ç¶ÔÑ)
  • particle immunoassay
    ÀÔÀÚ ¸é¿ª(Ø£í­Øóæ¹)¾Æ½êÀÌ
  • particle scattering factor
    ÀÔÀÚ »ê¶õÀÎÀÚ(Ø£í­ß¤Õ¯ì×í­)
  • particle weight
    ÀÔÀÚ·®(Ø£í­Õá)
  • PM particle
    PM ÀÔÀÚ(Ø£í­)
  • ribosomal particle
    ¶óÀ̺¸¼Ø ÀÔÀÚ(Ø£í­)
  • stripped particle
    ³ªÀÔÀÚ(Ñߨ£í­)
  • subribosomal particle
    ¾Æ(ä¬)¶óÀ̺¸¼Ø ÀÔÀÚ(Ø£í­)
  • transducing particle
    ÇüÁúµµÀÔ ÀÔÀÚ(û¡òõÓôìýØ£í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DI date of injury; defective interfering [particle]; dentinogenesis imperfecta; deoxyribonucleic acid i...
DIPI defective interfering particle induction
EDP electron dense particle; electronic data processing; end-diastolic pressure
ETP electron transport particle; entire treatment period; ephedrine, theophylline, phenobarbital; eustac...
IAP immunosuppressive acidic protein; inosinic acid pyrophosphorylase; Institute of Animal Physiology; i...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
mRNP messenger ribonucleoprotein particle
PA Particle Agglutination
PCFIA Particle Concentration Fluorescence Immuno Assay
PACIA Particle Counting ImmunoAssay
PIXE Particle Induced X-ray Emission
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • corrected reticulocyte count
    ?
  • count per minute
    ÀϺа£ Ä«¿îÆ®
  • dust count
    ¸ÕÁö °è»ê¹ý
  • full blood count
    ÀüÇ÷ ÃøÁ¤, Ç÷¾× ÃÑ·® ¼ö
  • leukocyte count
    ¹éÇ÷±¸ ¼ö »êÁ¤
  • leukocyte differential count
    ¹éÇ÷±¸ ºÐÈ­
  • reticulocyte count
    ¸Á»ó ÀûÇ÷±¸ ¼ö
  • salivary lactobacillus count
    Ÿ¾× À¯»ê±Õ Áö¼ö
  • total count of bacteria
    ÃÑ±Õ ¼ö °èÃø
  • viable count of bacteria
    »ý±Õ¼ö °èÃø
  • white blood cell count
    ¹éÇ÷¼ö
  • white blood count
    ¹éÇ÷¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
D.I. particle <abbreviation> Defective interfering particle.
(05 Mar 2000)
dressed particle <radiobiology> A particle plus its associated neutralising Debye sphere.
(09 Oct 1997)
intramembranous particle <cell biology> Particles (or complementary pits) seen in freeze fractured membranes. The cleavage plane is through the centre of the bilayer and the particles are usually assumed to represent Integral membrane proteins (or polymers of such proteins).
(18 Nov 1997)
either particle flux density The particle fluence rate, or energy flux density, the energy fluence rate of intensity.
Compare: fluence.
(05 Mar 2000)
elementary particle interactions The interactions of particles responsible for their scattering and transformations (decays and reactions). Because of interactions, an isolated particle may decay into other particles. Two particles passing near each other may transform, perhaps into the same particles but with changed momenta (elastic scattering) or into other particles (inelastic scattering). Interactions fall into three groups: strong, electromagnetic, and weak.
(12 Dec 1998)
trapped-particle instability <radiobiology> Slowly-growing class of instabilities driven by particles which cannot circulate freely in a toroidal system.
See: banana orbit.
(09 Oct 1997)
kappa particle <microbiology> Gram-negative bacterial endosymbiont of Paramoecium spp., (Caedobacter taeniospiralis) that confers the killer trait, infected Paramoecium are resistant to the toxin liberated by infected forms. Killing activity is associated with the induction of defective phage in the endosymbiont, leading to the release of R bodies, coded for by the phage genome and apparently of mis assembled phage coat protein.
(18 Nov 1997)
Zimmermann's elementary particle <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels.
Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation.
Synonym: thrombocytes.
(09 Oct 1997)
absolute CD4 count The number of helper T-lymphocytes in a cubic millimeter of blood. With HIV, the absolute CD4 count declines as the infection progresses. The absolute CD4 count is frequently used to monitor the extent of immune suppression in persons with HIV. Also called a T4 count.
(12 Dec 1998)
absolute eosinophil count <haematology, investigation> A measurement (cells per microlitre) of the number of eosinophils in a blood specimen.
This measurement is useful in the evaluation of autoimmune disease, allergies, eczema, leukaemia, asthma and hay fever. Normal absolute eosinophil counts are less than 350 cells/mcl (microlitre).
(27 Sep 1997)
Addis count A quantitative enumeration of the red blood count, white blood count, and casts in a 12-hr urine specimen; used to follow the progress of known renal disease.
(05 Mar 2000)
Arneth count The percentage distribution of polymorphonuclear neutrophils, based on the number of lobes in the nuclei (from 1 to 5).
See: Arneth index.
(05 Mar 2000)
b and t cell count A test that measures the respective quantities of B lymphocytes and T lymphocytes. This test is often performed in the analysis of an immune deficiency disorder. Normal values include: 68 to 75% of total lymphocytes are T lymphocytes and 10 to 20% are B lymphocytes.
Increased T-cell counts can indicate infectious mononucleosis, acute lymphocytic leukaemia or multiple myeloma.
Increased B lymphocytes can indicate chronic lymphocytic leukaemia, multiple myeloma, Waldenstrom's macroglobulinaemia or Di George syndrome. Decreased T-cells may indicate congenital T-cell deficiency, Wiskott-Aldrich syndrome or AIDS. Decreased B-cells may indicate acute lymphocytic leukaemia or a congenital immunoglobulin deficiency disorder.
(27 Sep 1997)
blood cell count A count of the number of leukocytes and erythrocytes per unit volume in a sample of venous blood. A complete blood count (cbc) also includes measurement of the haemoglobin, haematocrit, and erythrocyte indices.
(12 Dec 1998)
blood count <haematology, investigation> The determination of the proper number of red blood cells, white blood cells and platelets are present in the patients blood.
Acronym: FBC
(16 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • count in
    ¼À¿¡ ³Ö´Ù; ÇÑÆÐ¿¡ ³¢¿öÁÖ´Ù
  • count on
    ÀÇÁöÇÏ´Ù; ¹Ï´Ù
  • count out
    Á¦¿ÜÇÏ´Ù
  • count up
    ÇÕ°èÇÏ´Ù
  • blood count
    Ç÷±¸¼öÃøÁ¤
  • coli count
    (¹Ù´å¹° ¼Ó µîÀÇ)´ëÀå±ÕÀÇ ¼ö
  • count
    (ÃѼö¸¦ ¾Ë±âÀ§ÇØ)¼¼´Ù;°è»êÇÏ´Ù;¼À¿¡ ³Ö´Ù;Æ÷ÇÔ½ÃŰ´Ù;...ÀÇ Å¿À¸·Î ÇÏ´Ù;À¸·Î µ¹¸®´Ù;(...À»...À̶ó°í)»ý°¢ÇÏ´Ù;°£ÁÖÇÏ´Ù;¼ö¸¦ ¼¼´Ù;°è»êÇÏ´Ù;(...ºÎÅÍ...±îÁö)¼¼´Ù;¼À(°è»ê)¿¡ ³Ö´Ù;(¼À¿¡ ³ÖÀ»)°¡Ä¡°¡ ÀÖ´Ù;Áß¿äÇÏ´Ù;(..ÀÇ)°¡Ä¡(°ª¾îÄ¡)°¡ ÀÖ´Ù;(...¾È¿¡)Æ÷ÇԵǴÙ;(...À¸
  • count noun
    °¡»ê ¸í»ç
  • count palatine
    Èı⠷θ¶Á¦±¹ ÃÖ°í »ç·É°ü;µ¶ÀÏ È²Á¦ÀÇ Çã°¡·Î ÀϺΠ¿Õ±ÇÀ» Àڱ⠿µÅä¿¡¼­ Çà»çÇÏ´ø ¿µÁÖ;À×±Û·£µå ¹× ¾ÆÀÏ·£µåÀÇ ÁÖ ¿µÁÖ
  • count-out
    Á¤Á·¼ö(40¸í)¹Ì´Þ·Î ÀÎÇÑ À¯È¸;Á¦¿ÜÇ¥(¿¡ ÀÇÇÑ ³«¼±ÀÚ);Ä«¿îÆ®¾Æ¿ô a
  • head count
    ¿©·Ð(±¹¼¼)Á¶»ç
  • nose count
    Àοø¼ö ¼¼±â;´Ù¼ö°á
  • pollen count
    ²É°¡·çÀÇ ¼ö !
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á